2OFV

crystal structure of aminoquinazoline 1 bound to Lck


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2 Å
  • R-Value Free: 0.301 
  • R-Value Work: 0.274 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Discovery of Aminoquinazolines as Potent, Orally Bioavailable Inhibitors of Lck: Synthesis, SAR, and in Vivo Anti-Inflammatory Activity

DiMauro, E.F.Newcomb, J.Nunes, J.J.Bemis, J.E.Boucher, C.Buchanan, J.L.Buckner, W.H.Cee, V.J.Chai, L.Deak, H.L.Epstein, L.F.Faust, T.Gallant, P.Geuns-Meyer, S.D.Gore, A.Gu, Y.Henkle, B.Hodous, B.L.Hsieh, F.Huang, X.Kim, J.L.Lee, J.H.Martin, M.W.Masse, C.E.McGowan, D.C.Metz, D.Mohn, D.Morgenstern, K.A.Oliveira-dos-Santos, A.Patel, V.F.Powers, D.Rose, P.E.Schneider, S.Tomlinson, S.A.Tudor, Y.-Y.Turci, S.M.Welcher, A.A.White, R.D.Zhao, H.Zhu, L.Zhu, X.

(2006) J.Med.Chem. 49: 5671

  • DOI: 10.1021/jm0605482
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • The lymphocyte-specific kinase (Lck) is a cytoplasmic tyrosine kinase of the Src family expressed in T cells and natural killer (NK) cells. Genetic evidence in both mice and humans demonstrates that Lck kinase activity is critical for signaling media ...

    The lymphocyte-specific kinase (Lck) is a cytoplasmic tyrosine kinase of the Src family expressed in T cells and natural killer (NK) cells. Genetic evidence in both mice and humans demonstrates that Lck kinase activity is critical for signaling mediated by the T cell receptor (TCR), which leads to normal T cell development and activation. Selective inhibition of Lck is expected to offer a new therapy for the treatment of T-cell-mediated autoimmune and inflammatory disease. Screening of our kinase-preferred collection identified aminoquinazoline 1 as a potent, nonselective inhibitor of Lck and T cell proliferation. In this report, we describe the synthesis and structure-activity relationships of a series of novel aminoquinazolines possessing in vitro mechanism-based potency. Optimized, orally bioavailable compounds 32 and 47 exhibit anti-inflammatory activity (ED(50) of 22 and 11 mg/kg, respectively) in the anti-CD3-induced production of interleukin-2 (IL-2) in mice.


    Organizational Affiliation

    Department of Medicinal Chemistry, Amgen, Inc., Cambridge, Massachusetts 02139, USA. edimauro@amgen.com




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Proto-oncogene tyrosine-protein kinase LCK
A, B
277Homo sapiensMutation(s): 0 
Gene Names: LCK
EC: 2.7.10.2
Find proteins for P06239 (Homo sapiens)
Go to Gene View: LCK
Go to UniProtKB:  P06239
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
242
Query on 242

Download SDF File 
Download CCD File 
A, B
3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
AMINOQUINAZOLINE 1
C23 H17 F3 N4 O
YEIASMOUYNOXGA-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
242IC50: 0.2 - <1 nM (100) BINDINGDB
242IC50: 0.2 nM BINDINGMOAD
242IC50: 0.2 nM PDBBIND
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2 Å
  • R-Value Free: 0.301 
  • R-Value Work: 0.274 
  • Space Group: C 1 2 1
Unit Cell:
Length (Å)Angle (°)
a = 142.660α = 90.00
b = 66.890β = 112.00
c = 78.510γ = 90.00
Software Package:
Software NamePurpose
AMoREphasing
CNSrefinement
SCALEPACKdata scaling
DENZOdata reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2007-01-04 
  • Released Date: 2007-02-27 
  • Deposition Author(s): Huang, X.

Revision History 

  • Version 1.0: 2007-02-27
    Type: Initial release
  • Version 1.1: 2008-05-01
    Type: Version format compliance
  • Version 1.2: 2011-07-13
    Type: Version format compliance